Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline

  • ID: 4027869
  • Report
  • Region: Asia Pacific
  • 110 Pages
  • GBI Research
1 of 5
The Asia-Pacific Antihypertensive Market will be Valued at $27 Billion in 2022, Growing from $19.1 Billion in 2015 at a CAGR of 5.1%
Hypertension is a serious and common medical condition characterized by elevated blood pressure. It is commonly seen in the aging population, and in people with sedentary lifestyles and obesity. As one of the most significant preventable causes of death worldwide, early diagnosis of the condition is crucial to improve health outcomes. Hypertension is the key risk factor for stroke; according to the National Stroke Association (NSA), two-thirds of patients who suffer a stroke have hypertension.

The anti-hypertensive therapeutics market is expected to grow significantly over the forecast period across the five Asia-Pacific (APAC) markets, from $19.1 Billion in 2015 to $27 Billion by 2022, at a compound annual growth rate (CAGR) of 5.1%. This growth is primarily attributed to the increasingly elderly population - where the prevalence rate of hypertension is at the highest - and increases in risk factors such as being overweight or obese, high daily sodium intake, low physical activity levels, urbanization, consumption of alcohol, smoking, and mental stress. In the five assessed APAC countries, the total population aged 65 and over was 1 Billion in 2015, and this is expected to grow at a CAGR of 3.32% to reach 1.2 Billion in 2022 (US Census Bureau, 2016).

The antihypertensive pipeline consists of 112 pipeline products, most of which are small molecules. Most of the pipeline products are at early stages of development, with Discovery and Preclinical products accounting for 55%. Phase I, II and III products account for 40%, and Pre-registration products account for 4%.

In the five assessed APAC regions, the total estimated prevalence population of hypertension was approximately 548 million in 2015. Of these, approximately 335 million (61.1%) were undiagnosed. Moreover, among the diagnosed patients, approximately 104.7 million (49.1%) were untreated, while 108.5 million (50.9%) were treated with drug therapy. The low diagnosis and treatment rates are primarily due to the lack of awareness of the condition among healthcare professionals, patients, and the public. The asymptomatic nature of the disease is another major factor limiting the diagnosis rate, and a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China is another contributing factor.

Moreover, two major marketed products, Benicar/Olmetec (olmesartan medoxomil), and Rasilez (aliskiren), are expected to see their patents expire in Japan and Australia during the forecast period. The patent of Olmetec is expected to expire in Japan in 2016 and Australia in 2017, while the patent of Rasilez (aliskiren) is expected to expire in Australia in 2020. Increasing generic competition across the five APAC regions will restrict market growth during the forecast period.

The report “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline” provides an introduction to anti-hypertensive, detailing the epidemiology, etiology, diagnostic techniques, pathophysiology, disease staging and prognoses for patients.

In depth, it provides the following:
  • Detailed analysis of the drugs currently marketed for anti-hypertensive (Cozaar, Benicar, Micardis, Diovan, Azilva, Norvasc, Rasilez, Tritace, Carvedilol, Prestalia, Exforge).
  • Provides detailed analysis of the pipeline for anti-hypertensive, by stage of development, molecule type, program type, mechanism of action and molecular target.
  • Detailed analysis of recent clinical trials in this indication, by enrollment, duration and failure rate. Promising late-stage pipeline molecules are analyzed and assessed in terms of their potential competitive strength.
  • Supplies forecasts for the anti-hypertensive markets, including epidemiology, treatment usage patterns, pricing and market size for the 2015-2022 period. The five APAC markets are covered, and data are presented at a country level.
  • Detailed analysis of the key market drivers and barriers for the anti-hypertensive markets.
  • Describes the major deals that have taken place in the global anti-hypertensive markets in recent years. This coverage analyzes licensing and co-development agreements, segmented by stage of development, year, molecule type, mechanism of action and value.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

1. Table of Contents

2 Introduction
2.1 Disease Introduction
2.2 Epidemiology
2.3 Symptoms
2.4 Etiology and Pathophysiology
2.5 Diagnosis
2.5.1 Office or Clinic Blood Pressure Monitoring
2.5.2 Automated Office Blood Pressure Measurement
2.5.3 Ambulatory Blood Pressure Monitoring
2.5.4 Home Blood Pressure Monitoring
2.5.5 Miscellaneous Methods
2.5.6 Diagnosis of Target Organ Damage
2.5.7 Diagnosis of Hypertension in Pregnancy
2.6 Prognosis
2.7 Disease Stage
2.8 Treatment Options
2.8.1 Treatment Algorithm
2.8.2 Pharmacological Treatment
2.8.3 Non-pharmacological Treatment

3 Marketed Products
3.1 Angiotensin II Receptor Antagonists
3.1.1 Losartan - Merck & Co
3.1.2 Olmesartan - Daiichi Sankyo
3.1.3 Olmesartan + Amlodipine + Hydrochlorothiazide - Daiichi Sankyo
3.1.4 Valsartan - Novartis
3.1.5 Telmisartan - Boehringer Ingelheim
3.1.6 Azilsartan Medoxomil - Takeda
3.2 Calcium Channel Blockers
3.2.1 Amlodipine - Pfizer
3.3 Renin Inhibitors
3.3.1 Aliskiren - Novartis
3.4 Angiotensin Converting Enzyme Inhibitors
3.4.1 Ramipril - Sanofi
3.5 Beta Blockers
3.5.1 Carvedilol - GlaxoSmithKline
3.6 Multiple Drug Class Combinations
3.6.1 Perindopril Arginine + Amlodipine Besylate - Les Laboratoires Servier
3.6.2 Amlodipine + Valsartan - Novartis
3.7 Comparative Efficacy and Safety of Marketed Products

4 Pipeline Analysis
4.1 Overview
4.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
4.3 Pipeline by Molecular Target
4.4 Promising Pipeline Candidates
4.4.1 CS-3150

5 Clinical Trial Analysis
5.1 Failure Rate
5.1.1 Overall Failure Rate
5.1.2 Failure Rate by Phase and Molecule Type
5.1.3 Failure Rate by Phase and Molecular Target
5.2 Clinical Trial Duration
5.2.1 Clinical Trial Duration by Molecule Type
5.2.2 Clinical Trial Duration by Molecular Target
5.3 Clinical Trial Size
5.3.1 Patient Enrollment per Trial by Molecule Type, Molecular Target and Stage of Development
5.3.2 Patient Enrollment per Product by Molecule Type, Molecular Target and Stage of Development
5.4 Competitive Clinical Trials Metrics Analysis

6 Multi-Scenario Forecast
6.1.1 Geographical Markets
6.1.2 Asia-Pacific Market
6.2 India
6.2.1 Treatment Use Patterns
6.2.2 Annual Cost of Therapy
6.2.3 Market Size
6.3 China
6.3.1 Treatment Use Patterns
6.3.2 Annual Cost of Therapy
6.3.3 Market Size
6.4 Australia
6.4.1 Treatment Use Patterns
6.4.2 Annual Cost of Therapy
6.4.3 Market Size
6.5 South Korea
6.5.1 Treatment Usage Patterns
6.5.2 Annual Cost of Therapy
6.5.3 Market Size
6.6 Japan
6.6.1 Treatment Use Patterns
6.6.2 Annual Cost of Therapy
6.6.3 Market Size

7 Drivers and Barriers
7.1 Drivers
7.1.1 Increasing Aging Populations to Increase Prevalence
7.1.2 Increasing Overweight and Obese Population
7.1.3 Increase in Daily Sodium Intake
7.1.4 Sedentary Lifestyle or Less Physical Activity
7.1.5 High Prevalence of Smoking and Alcoholism
7.1.6 Diversified Healthcare Reform to Boost Market Growth
7.2 Barriers
7.2.1 Weak Pipeline and Widespread Usage of Generic Drugs
7.2.2 Non-pharmacological First-Line Treatment
7.2.3 Lack of Awareness of the Disease Condition

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.1.1 Deals by Region and Value
8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.1.4 Key Licensing Deals
8.2 Co-development Deals
8.2.1 Deals by Region and Value
8.2.2 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
8.2.4 Key Co-development Deals

9 Appendix
9.1 All Pipeline Drugs by Stage of Development
9.1.1 Discovery
9.1.2 Preclinical
9.1.3 Investigational New Drug/ Clinical Trial Authorization-Filed
9.1.4 Phase I
9.1.5 Phase II
9.1.6 Phase III
9.1.7 Pre-registration
9.2 Market Forecasts to 2022
9.2.1 Asia-Pacific
9.2.2 India
9.2.3 China
9.2.4 Australia
9.2.5 South Korea
9.2.6 Japan
9.3 Reference
9.4 Abbreviations
9.5 Research Methodology
9.5.1 Secondary Research
9.5.2 Marketed Product Profiles
9.5.3 Late-Stage Pipeline Candidates
9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
9.5.5 Product Competitiveness Framework
9.5.6 Pipeline Analysis
9.5.7 Forecasting Model
9.5.8 Deals Data Analysis

List of Tables

Table 1: Anti-hypertensive Therapeutics, Prevalence Rate
Table 2: Anti-hypertensive Therapeutics, Definitions of Hypertension by Office and Out-of-Office Blood Pressure Levels (mmHg)
Table 3: Anti-hypertensive Therapeutics, Proposal for Outcome-Driven Reference Values for Ambulatory Blood Pressure Measurement (mmHg)
Table 4: Anti-hypertensive Therapeutics, Blood Pressure Stages in Adults (mmHg)
Table 5: Anti-hypertensive Therapeutics, Compelling and Possible Contra-indications of Anti-hypertensive Drugs
Table 6: Anti-hypertensive Therapeutics, Lifestyle Measures and Recommendations
Table 7: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Discovery, 2016
Table 8: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Preclinical, 2016
Table 9: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Investigational New Drug, 2016
Table 10: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase I, 2016
Table 11: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase-II, 2016
Table 12: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Phase III, 2016
Table 13: Anti-hypertensive Therapeutics Market, Global, All Pipeline Products, Pre-registration, 2016
Table 14: Anti-hypertensive Therapeutics Market, Asia-Pacific, Market Forecast, 2015-2022
Table 15: Anti-hypertensive Therapeutics Market, India, Market Forecast, 2015-2022
Table 16: Anti-hypertensive Therapeutics Market, China, Market Forecast, 2015-2022
Table 17: Anti-hypertensive Therapeutics Market, Australia, Market Forecast, 2015-2022
Table 18: Anti-hypertensive Therapeutics Market, South Korea, Market Forecast, 2015-2022
Table 19: Anti-hypertensive Therapeutics Market, Japan, Market Forecast, 2015-2022
Table 20: Abbreviations

List of Figures

Figure 1: Anti-hypertensive Therapeutics, Global, Hypertension Prevalence Rate (%), 2009-2012
Figure 2: Anti-hypertensive Therapeutics, Physiological Mechanism of Renin-Angiotensin-Aldosterone System
Figure 3: Anti-hypertensive Therapeutics: Blood Pressure Measurements and Examination of a Patient to Detect Hypertension
Figure 4: Anti-hypertensive Therapeutics, Treatment Algorithm of Hypertension
Figure 5: Anti-hypertensive Therapeutics, Combination Therapy Strategies for Blood Pressure Reduction
Figure 6: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Hypertension
Figure 7: Anti-hypertensive Market, Comparative Efficacy and Safety Heatmap for Marketed Products for Pediatrics for the Treatment of Hypertension
Figure 8: Anti-hypertensive Therapeutics Market, Global, Pipeline, 2016
Figure 9: Anti-hypertensive Therapeutics Market, Global, Pipeline by Molecular Target, 2016
Figure 10: Anti-hypertensive Therapeutics, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 11: Anti-hypertensive Therapeutics, Global, Average Clinical Trial Failure Rate (%), 2016
Figure 12: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecule Type (%), 2006-2015
Figure 13: Anti-hypertensive Therapeutics, Global, Clinical Trial Failure Rate by Molecular Target (%), 2006-2015
Figure 14: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Stage of Development and Molecule Type, 2006-2015
Figure 15: Anti-hypertensive Therapeutics, Global, Clinical Trial Duration by Molecular Target, 2006-2015
Figure 16: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Type, 2006-2015
Figure 17: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Trial by Molecular Target, 2006-2015
Figure 18: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecule Type, 2006-2015
Figure 19: Anti-hypertensive Therapeutics, Global, Clinical Trial Size per Product by Molecular Target, 2006-2015
Figure 20: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecule Type
Figure 21: Anti-hypertensive Therapeutics Market, Global, Comparison of Average Trial Metrics by Phase and Molecular Target
Figure 22: Anti-hypertensive Therapeutics Market, Asia-Pacific, Treatment Patterns (million) and Market Size ($bn), 2015-2022
Figure 23: Anti-hypertensive Therapeutics Market, India, Treatment Patterns (million), 2015-2022
Figure 24: Anti-hypertensive Therapeutics Market, India, Annual Cost of Therapy ($), 2015-2022
Figure 25: Anti-hypertensive Therapeutics Market, India, Market Size ($bn), 2015-2022
Figure 26: Anti-hypertensive Therapeutics Market, China, Treatment Patterns (million), 2015-2022
Figure 27: Anti-hypertensive Therapeutics Market, China, Annual Cost of Therapy ($), 2015-2022
Figure 28: Anti-hypertensive Therapeutics Market, China, Market Size ($bn), 2015-2022
Figure 29: Anti-hypertensive Therapeutics Market, Australia, Treatment Patterns (million), 2015-2022
Figure 30: Anti-hypertensive Therapeutics Market, Australia, Annual Cost of Therapy ($), 2015-2022
Figure 31: Anti-hypertensive Therapeutics Market, Australia, Market Size ($bn), 2015-2022
Figure 32: Anti-hypertensive Therapeutics Market, South Korea, Treatment Patterns (million), 2015-2022
Figure 33: Anti-hypertensive Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2015-2022
Figure 34: Anti-hypertensive Therapeutics Market, South Korea, Market Size ($bn), 2015-2022
Figure 35: Anti-hypertensive Therapeutics Market, Japan, Treatment Patterns (million), 2015-2022
Figure 36: Anti-hypertensive Therapeutics Market, Japan, Annual Cost of Therapy ($), 2015-2022
Figure 37: Anti-hypertensive Therapeutics Market, Japan, Market Size ($bn), 2015-2022
Figure 38: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Region and Value, 2006-2016
Figure 39: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 40: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2016
Figure 41: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2006-2016
Figure 42: Anti-hypertensive Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2006-2016
Figure 43: Anti-hypertensive Therapeutics Market, Global, Co-development Deals by Region and Deal Value, 2006-2016
Figure 44: Anti-hypertensive Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2006-2016
Figure 45: Anti-hypertensive Therapeutics, Global, Co-development Deals by Phase and Mechanism of Action, 2006-2016

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

Asia-Pacific anti-hypertensive therapeutics market to hit $27 billion by 2022, despite low innovation.

The market for anti-hypertensive therapeutics across the five Asia-Pacific (APAC) countries of India, China, Australia, South Korea, and Japan, is set to grow from $19.1 billion in 2015 to $27 billion by 2022, at a compound annual growth rate of 5.1%.

The company’s latest report states that this relatively solid rise in market value will be driven by the increasingly elderly population – where the prevalence rate of hypertension is highest – and increases in risk factors such as obesity, low physical activity levels, urbanization, and smoking. Indeed, growth will not be aided by the weak anti-hypertensive pipeline, due to lack of innovative products in late-stage development.

Gautam Arora, Analyst, explains: “The anti-hypertensive pipeline consists of 112 pipeline products, most of which are small molecules. The limited presence of other types of molecules in the pipeline suggests that large pharmaceutical companies are refraining from developing novel molecules and are more inclined to focus on patient-compliant combination therapies. It is therefore unlikely that any completely novel molecules will enter the market during the forecast period.

“Prestalia is an example of a recently improved drug that offers an improvement to hypertension therapy. In a Phase III trial it provided a better benefit-to-risk ratio than either treatment alone. The drug was approved by the US FDA in January 2015, and it is marketed by Symplmed. Of the APAC countries covered in the report, however, it is available only in Australia, and it is under development in Japan and South Korea.”

Overall, late-stage products will not change the treatment paradigm of hypertension during the forecast period. With the lack of any new premium-priced drugs in this setting and the prescription of relatively cheap generic versions of anti-hypertensive drugs to continue, it's expected the status quo of drug treatment will persist in the APAC region.

Arora concludes: “Despite the availability of a large number of blood-pressure-lowering agents, the need remains for safer and more effective anti-hypertensive treatments. Although the APAC market is likely to see steady growth, it will continue to be obstructed by a weak pipeline and low diagnosis and treatment rates.

“Indeed, the asymptomatic nature of the disease along with a lack of frequent blood pressure checks due to limited affordability and healthcare accessibility in countries such as India and China can limit diagnosis rates.”

  • Comments provided by Gautam Arora, Analyst.
  • Information based on the report: “Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2022 - Increasing Prevalence of Hypertension Drives Market Growth despite Weak Pipeline”.
  • This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by a team of industry experts.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll